Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Citi raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, ...

FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...

Recently, Eli Lilly (LLY) revealed that they saw some concerning indicators for their GLP-1 drug in December, which might have been the culprit behind them missing their Q4 revenue guidance by $400M.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare ... For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates of $4.4 billion.

US Dollar South African Rand, Coca-Cola Co, Eli Lilly and Company, Apple Inc. Read Vestact 's latest article on Investing.com South Africa.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...